We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S 910823...

We examined 79 Japanese MNCs' R&D subsidiaries in the US from the knowledge-based view. We find: (1) subsidiaries' R&D strategies generally encourage knowledge flows; (2) subsidiaries' R&D alliances promote knowledge flows; (3) R&D subsidiaries with process-oriented incentives promote vertical...